Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
• 1.4 Market by Type
  • 1.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Anti VEGF Drugs
  • 1.4.3 Photosensitive Drugs
  • 1.4.4 Others
• 1.5 Market by Application
  • 1.5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Exudative ARMD
  • 1.5.3 Atrophy ARMD
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2015-2026)
• 2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Regions
  • 2.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Age-relatedMacularDegeneration (ARMD) Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Market Size
  • 3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
  • 3.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2019
• 3.3 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
• 3.4 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
• 3.5 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)
• 5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 6.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in North America (2019-2020)
• 6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 7.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Europe (2019-2020)
• 7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 8.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in China (2019-2020)
• 8.3 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 8.4 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 9.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Japan (2019-2020)
• 9.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 9.4 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 10.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 11.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in India (2019-2020)
• 11.3 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 11.4 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
• 12.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

13Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview
  • 13.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Regeneron Pharmaceuticals
  • 13.2.1 Regeneron Pharmaceuticals Company Details
  • 13.2.2 Regeneron Pharmaceuticals Business Overview
  • 13.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.2.5 Regeneron Pharmaceuticals Recent Development
• 13.3 Bayer
  • 13.3.1 Bayer Company Details
  • 13.3.2 Bayer Business Overview
  • 13.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.3.5 Bayer Recent Development
• 13.4 Santen Oy
  • 13.4.1 Santen Oy Company Details
  • 13.4.2 Santen Oy Business Overview
  • 13.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.4.5 Santen Oy Recent Development
• 13.5 Kanghong Pharmaceuticals
  • 13.5.1 Kanghong Pharmaceuticals Company Details
  • 13.5.2 Kanghong Pharmaceuticals Business Overview
  • 13.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.5.5 Kanghong Pharmaceuticals Recent Development
• 13.6 Novartis
  • 13.6.1 Novartis Company Details
  • 13.6.2 Novartis Business Overview
  • 13.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.6.5 Novartis Recent Development
• 13.7 Eli Lilly and Company
  • 13.7.1 Eli Lilly and Company Company Details
  • 13.7.2 Eli Lilly and Company Business Overview
  • 13.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.7.5 Eli Lilly and Company Recent Development
• 13.8 TRACON Pharmaceuticals
  • 13.8.1 TRACON Pharmaceuticals Company Details
  • 13.8.2 TRACON Pharmaceuticals Business Overview
  • 13.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.8.5 TRACON Pharmaceuticals Recent Development
• 13.9 Pfizer
  • 13.9.1 Pfizer Company Details
  • 13.9.2 Pfizer Business Overview
  • 13.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.9.5 Pfizer Recent Development
• 13.10 GSK
  • 13.10.1 GSK Company Details
  • 13.10.2 GSK Business Overview
  • 13.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 13.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 13.10.5 GSK Recent Development
• 13.11 BIOCAD
  • 10.11.1 BIOCAD Company Details
  • 10.11.2 BIOCAD Business Overview
  • 10.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  • 10.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  • 10.11.5 BIOCAD Recent Development

14Analyst's Viewpoints/Conclusions

15Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer